Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

Richard S. Finn; Katalin Boer; Igor Bondarenko; Ravindranath Patel; Tamas Pinter; Marcus Schmidt; Yaroslav V. Shparyk; Anu Thummala; Nataliia Voitko; Eustratios Bananis; Lynn McRoy; Keith Wilner; Xin Huang; Sindy Kim; Dennis J. Slamon; Johannes Ettl

doi:10.1007/s10549-020-05755-7

Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

Breast Cancer Research and Treatment ◽

10.1007/s10549-020-05755-7 ◽

2020 ◽

Vol 183 (2) ◽

pp. 419-428 ◽

Cited By ~ 1

Author(s):

Richard S. Finn ◽

Katalin Boer ◽

Igor Bondarenko ◽

Ravindranath Patel ◽

Tamas Pinter ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Study ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

100O Results of A Randomized Phase 2 Study of Pd 0332991, A Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, In Combination with Letrozole vs Letrozole Alone For First-Line Treatment of ER + /Her2- Advanced Breast Cancer (Bc)

Annals of Oncology ◽

10.1093/annonc/mds045 ◽

2012 ◽

Vol 23 ◽

pp. ii43 ◽

Cited By ~ 18

Author(s):

R.S. Finn ◽

J.P. Crown ◽

K. Boer ◽

I. Lang ◽

R.J. Parikh ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Line Treatment ◽

Phase 2 ◽

Cyclin Dependent Kinase ◽

First Line ◽

Phase 2 Study ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)

10.1158/0008-5472.sabcs12-s1-6 ◽

2012 ◽

Cited By ~ 34

Author(s):

RS Finn ◽

JP Crown ◽

I Lang ◽

K Boer ◽

IM Bondarenko ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Line Treatment ◽

Phase 2 ◽

Cyclin Dependent Kinase ◽

First Line ◽

Phase 2 Study ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(14)71159-3 ◽

2015 ◽

Vol 16 (1) ◽

pp. 25-35 ◽

Cited By ~ 947

Author(s):

Richard S Finn ◽

John P Crown ◽

Istvan Lang ◽

Katalin Boer ◽

Igor M Bondarenko ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Oestrogen Receptor ◽

Advanced Breast ◽

Line Treatment ◽

Phase 2 ◽

Cyclin Dependent Kinase ◽

First Line ◽

Phase 2 Study ◽

First Line Treatment

Download Full-text

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study

Cancer Medicine ◽

10.1002/cam4.3091 ◽

2020 ◽

Vol 9 (14) ◽

pp. 4929-4940 ◽

Cited By ~ 2

Author(s):

Masato Takahashi ◽

Norikazu Masuda ◽

Reiki Nishimura ◽

Kenichi Inoue ◽

Shinji Ohno ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Study ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725283758.793525555 ◽

2016 ◽

Cited By ~ 1

Author(s):

Daniel Vorobiof

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Oestrogen Receptor ◽

Advanced Breast ◽

Line Treatment ◽

Phase 2 ◽

Cyclin Dependent Kinase ◽

First Line ◽

Phase 2 Study ◽

First Line Treatment

Download Full-text

P1-17-05: Preliminary Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole for First-Line Treatment of Patients (pts) with Post-Menopausal, ER+, HER2−Negative (HER2–) Advanced Breast Cancer.

10.1158/0008-5472.sabcs11-p1-17-05 ◽

2011 ◽

Cited By ~ 1

Author(s):

RS Finn ◽

JP Crown ◽

K Boer ◽

I Lang ◽

RJ Parikh ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Line Treatment ◽

Phase 2 ◽

Cyclin Dependent Kinase ◽

First Line ◽

Phase 2 Study ◽

Post Menopausal ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

5060 POSTER Albumin-bound Paclitaxel (ab-pac) Versus Docetaxel for First-line Treatment of Metastatic Breast Cancer (MBC): Overall Survival (OS) Subset Analyses of a Randomized Phase 2 Trial

European Journal of Cancer ◽

10.1016/s0959-8049(11)71502-7 ◽

2011 ◽

Vol 47 ◽

pp. S348

Author(s):

W.J. Gradishar ◽

D.A. Krasnojon ◽

S.V. Cheporov ◽

A.N. Makhson ◽

G.M. Manikhas ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

First Line Treatment

Download Full-text

A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2019.09.008 ◽

2020 ◽

Vol 15 (1) ◽

pp. 91-100 ◽

Cited By ~ 4

Author(s):

James Chih-Hsin Yang ◽

Ying Cheng ◽

Haruyasu Murakami ◽

Pan-Chyr Yang ◽

Jianxing He ◽

...

Keyword(s):

Overall Survival ◽

Egfr Mutation ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Phase 2 Study ◽

Biomarker Analysis ◽

Randomized Phase 2 ◽

Nonsquamous Nsclc ◽

First Line Treatment

Download Full-text

Abstract S6-04: Fulvestrant 500 mg versus anastrozole as first-line treatment for advanced breast cancer: Overall survival from the Phase II ‘FIRST’ study

10.1158/1538-7445.sabcs14-s6-04 ◽

2015 ◽

Cited By ~ 15

Author(s):

John FR Robertson ◽

Antonio Llombart-Cussac ◽

David Feltl ◽

John Dewar ◽

Marek Jasiówka ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Advanced Breast ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

Vinorelbine Plus Gemcitabine or Cisplatin as First-line Treatment of HER2-negative Advanced Breast Cancer

10.21873/anticanres.12000 ◽

2017 ◽

Vol 37 (10) ◽

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text